SCHEMBL1504567

SCHEMBL1504567

Cc1ccc(C(=O)O)cc1NC(=O)c1ccc(=O)n(-c2c(Cl)cccc2Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
CREBBP Q92793 1/20 0.46
PPARG P37231 1/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HDAC8 Q9BY41 2/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MAPT P10636 4/20 0.43
POLB P06746 1/20 0.43
NPC1 O15118 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 2/20 0.42
XPO1 O14980 1/20 0.42
PTPN7 P35236 1/20 0.42
PTPN22 Q9Y2R2 1/20 0.42
LMNA P02545 1/20 0.41
HPSE Q9Y251 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504505 0.90 HDAC1 (0.48) CREBBPPPARGALDH1A1HDAC8HDAC1
SCHEMBL1504173 0.88 MAPK14 (0.55)
SCHEMBL1504759 0.86 IDH2 (0.44) CREBBPALDH1A1MAPTPOLBNPC1
SCHEMBL1504559 0.83 MAPK14 (0.52) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL1504507 0.83 HDAC1 (0.44) CREBBPPPARGALDH1A1HDAC8HDAC1
SCHEMBL1504127 0.82 MEN1 (0.45) CREBBPPPARGALDH1A1KDM4EHDAC8
SCHEMBL1504734 0.82 MAPK14 (0.53)
SCHEMBL1504519 0.81 PPARG (0.43) CREBBPPPARGALDH1A1HDAC8HDAC1
SCHEMBL1504720 0.80 NPC1 (0.47) ALDH1A1KDM4EMAPTPOLBNPC1
SCHEMBL1504557 0.80 HDAC1 (0.45) CREBBPPPARGALDH1A1HDAC8HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
EP-2155683-B1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC (JP) 2011-03-16 EP disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS MAPK1, MAPK6, MAPK3 L3MBTL1 2628/4885CREBBP 1627/4885PPARG 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.